Table 2.

CD8+ T-cell responses to PR1 following SCT in patients with CML, ALL, and solid tumor

Patients	UPN	D30 (%)	D45 (%)	D60 (%)	D90 (%)	D120–180 (%)	Late time point (%) (months post-SCT)	D180 MRD (BCR-ABL/ABL)
CML
	Pt1	NA	0.34	NA	NA	NA	0.02 (84 m)	Neg
	Pt2	NA	0.12	NA	0.05	NA	0.14 (24 m)	Pos
	Pt3	0.18	0.06	0.00	0.00	NA	0.00 (24 m)	Neg
	Pt4	NA	0.02	0.02	0.00	0.04		Pos
	Pt5	NA	NA	0.24	0.10	0.10	0.07 (40 m)	Neg
	Pt6	NA	0.16	0.55	0.27	0.00		Neg
	Pt7	0.17	0.00	0.00	0.00	0.00	0.00 (48 m)	Neg
	Pt8	NA	NA	0.11	NA	NA	0.00 (60 m)	Pos
	Pt9	0.49	0.10	0.18	0.00	NA	0.00 (30 m)	Neg
	Pt10	0.28	0.13	0.12	0.19	NA	0.07 (48 m)	Neg
	Pt11	0.00	0.17	1.72	NA	NA	0.04 (47 m)	Neg
	Pt12	NA	NA	0.00	NA	NA	0.00 (61 m)	Pos
	Pt13	0.00	0.00	0.00	0.00	NA	0.00 (47 m)	Pos
ALL								D180 MRD WT1/ABL)
	Pt14	NA	0.00	0.30	0.03	0.04		Pos
	Pt15	NA	NA	0.04	NA	0.04	0.00 (96 m)	Pos
	Pt16	0.14	0.00	0.00	0.05	0.17	NA	Pos
	Pt17	0.00	0.03	0.14	0.00	NA	NA	Neg
	Pt18	0.14	0.03	0.07	0.12	0.00		Pos
	Pt19	0.23	0.05	0.32	0.21	NA	NA	Neg
	Pt20	0.00	0.06	0.05	NA	NA	NA	Pos
	Pt21	0.00	0.00	0.00	0.00	NA	NA	Neg
	Pt22	0.00	0.00	0.00	0.00	0.00	NA	Neg
Solid tumor
	Pt23	0.10	NA	0.00	0.00	NA		N/A
	Pt24	0.40	0.10	0.00	0.00	0.00	NA	N/A
	Pt25	0.20	0.10	NA	0.10	0.00	NA	N/A
	Pt26	0.00	0.00	0.00	0.00	0.00	NA	N/A
	Pt27	NA	0.09	0.10	0.10	0.10	NA	N/A

Tetramer analysis of PBMCs was performed by 6-color flow cytometry. The frequency of PR1/HLA-A*0201+ CD8+ T cells in samples at specific time points and MRD status at D+ 180 after SCT are presented. Because of the limited patient material, not all time points could be tested for each patient. N/A not available